Alcon reports PhIII win for dry eye drug, plans mid-2024 FDA filingnews2024-01-10T11:22:27+00:00January 10th, 2024|Endpoints News|
#JPM24: Walgreens’ new CEO unpacks how the chain will survive as a standalone businessnews2024-01-10T06:48:14+00:00January 10th, 2024|Endpoints News|
#JPM24: Walgreens CEO says it would be easy for UK pharmacy operation Boots to run separately amid talks of splittingnews2024-01-10T06:31:03+00:00January 10th, 2024|Endpoints News|
#JPM24: Paul Hudson is ‘open-minded’ to M&A as he plots Sanofi’s transformationnews2024-01-09T23:13:39+00:00January 9th, 2024|Endpoints News|
#JPM24 quick hits: Vibe check; Maze’s next turn; AI at pharma companies + morenews2024-01-09T22:51:11+00:00January 9th, 2024|Endpoints News|
Spain’s Grifols accused of manipulating finances by short seller Gotham City, stock plummets news2024-01-09T21:43:13+00:00January 9th, 2024|Endpoints News|
Lupus drug market growing as physicians adopt newer options — and look for more, research findsnews2024-01-09T21:06:49+00:00January 9th, 2024|Endpoints News|
FDA chief taps Elizabeth Jungman as new chief of staff, starting later this monthnews2024-01-09T20:35:24+00:00January 9th, 2024|Endpoints News|
As Congress debates orphan reforms, new analysis finds 65% of orphan drugs approved for a single rare diseasenews2024-01-09T19:56:33+00:00January 9th, 2024|Endpoints News|
MiMedx receives FDA warning letter over Axiofill manufacturing concernsnews2024-01-09T19:29:10+00:00January 9th, 2024|Endpoints News|
